[Form 4] LeMaitre Vascular, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Lawrence J. Jasinski, a director of LeMaitre Vascular, Inc. (LMAT), reported on Form 4 that on 09/04/2025 he received dividend equivalent rights tied to previously granted equity awards. The Form 4 lists five separate accruals of dividend equivalent rights that arose from restricted stock unit and performance stock unit awards granted on 12/12/2022, 12/8/2023 and 12/6/2024. Each dividend equivalent right is described as the economic equivalent of one share of common stock and vests proportionately with the underlying award. The filing shows fractional share amounts for each accrual and the number of shares beneficially owned following the transactions. The Form 4 was signed by Nathan Ulrich on 09/08/2025.

Positive

• Transparency: The company disclosed accruals of dividend equivalent rights for a director, providing clear insider compensation information.
• Non-cash nature: The accruals are described as dividend equivalent rights that vest with underlying RSUs/PSUs, not open-market transactions.

Negative

• None.

Insights

Securities Analyst

TL;DR: Director accrued small fractional dividend-equivalent rights from prior RSU/PSU grants; routine, non-cash accruals with limited immediate dilution.

The filing documents the accrual of dividend equivalent rights on 09/04/2025 tied to previously granted restricted stock units and performance stock units. These are economic equivalents of common shares that vest with the underlying awards and do not reflect open-market purchases or sales. The amounts reported are fractional and derived from award schedules rather than new issuance pricing. For investors, this is a disclosure of insider compensation mechanics rather than an actionable change in ownership control.

Corporate Governance Expert

TL;DR: Routine compensation accounting disclosure; shows ongoing vesting of equity awards for a director, not a change in governance.

The Form 4 clarifies that dividend equivalent rights accrued on RSU and PSU grants from 2022, 2023 and 2024 and vest proportionately with those awards. The filing identifies the reporting person as a director and indicates the form was filed by one reporting person. There is no indication of option exercise, cash consideration, or a change in director status. This disclosure supports transparency around insider compensation but does not indicate a governance event.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Jasinski Lawrence J

(Last) (First) (Middle)

C/O LEMAITRE VASCULAR, INC.

63 SECOND AVENUE

(Street)

BURLINGTON MA 01803

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
LEMAITRE VASCULAR INC [ LMAT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
09/04/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Dividend Equivalent Rights	(1)	09/04/2025		A		0.4173		(1)	(1)	Common Stock	0.4173	$0	6.5156	D
Dividend Equivalent Rights	(2)	09/04/2025		A		0.4173		(2)	(2)	Common Stock	0.4173	$0	5.5269	D
Dividend Equivalent Rights	(3)	09/04/2025		A		0.7138		(3)	(3)	Common Stock	0.7138	$0	5.3975	D
Dividend Equivalent Rights	(4)	09/04/2025		A		0.8546		(4)	(4)	Common Stock	0.8546	$0	5.8691	D
Dividend Equivalent Rights	(5)	09/04/2025		A		0.8697		(5)	(5)	Common Stock	0.8697	$0	2.9094	D

Explanation of Responses:

1. These dividend equivalent rights accrued on a restricted stock unit award granted on 12/12/2022 and vest proportionately with such award. Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock.

2. These dividend equivalent rights accrued on a Performance Stock Unit (PSU) award granted on 12/12/2022 and vest proportionately with such award. Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock.

3. These dividend equivalent rights accrued on a restricted stock unit award granted on 12/8/2023 and vest proportionately with such award. Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock.

4. These dividend equivalent rights accrued on a Performance Stock Unit (PSU) award granted on 12/8/2023 and vest proportionately with such award. Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock.

5. These dividend equivalent rights accrued on a restricted stock unit award granted on 12/6/2024 and vest proportionately with such award. Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock.

	/s/ Nathan Ulrich	09/08/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Lawrence J. Jasinski report on Form 4 for LMAT?

He reported accruals of dividend equivalent rights on 09/04/2025 tied to prior RSU and PSU awards; each right is the economic equivalent of one common share.

Do the reported transactions represent purchases or sales of LMAT stock?

No. The filing shows accruals of dividend equivalent rights (non-cash awards) that vest with underlying equity grants, not open-market trades.

From which award grants did the dividend equivalent rights accrue?

They accrued from restricted stock unit awards and performance stock unit awards granted on 12/12/2022, 12/8/2023 and 12/6/2024.

When were the transactions and when was the Form 4 signed?

The dividend equivalent rights accrued on 09/04/2025 and the Form 4 was signed by Nathan Ulrich on 09/08/2025.

Did the Form 4 disclose prices paid for these rights?

No. The filing shows these as dividend equivalent rights with $0 price and fractional share amounts; no cash consideration or exercise price is reported.